Fisher R L, Fisher S
Department of Psychiatry, State University of New York, Syracuse, 13210, USA.
J Nerv Ment Dis. 1996 Feb;184(2):99-102. doi: 10.1097/00005053-199602000-00006.
This article is concerned with issues pertaining to the degree to which clinical therapeutic decisions can reasonably depart from the best available scientific data. There is a tension between the traditions of practitioner autonomy and the boundaries set by research findings. Ambiguity exists as to how much freedom practitioners have to accept or reject the existing scientific paradigm. The nature of the dilemma is explored by analyzing the current problems confronting child psychiatrists and pediatricians who choose to treat depressed children with antidepressants. Despite unanimous literature of double-blind studies indicating that antidepressants are no more effective than placebos in treating depression in children and adolescents, such medications continue to be in wide use. The strategies used to resolve this sort of contradiction are considered, and certain ethical puzzles are appraised.
本文关注的问题是临床治疗决策在多大程度上能够合理地偏离现有的最佳科学数据。从业者自主性的传统与研究结果所设定的界限之间存在着矛盾。对于从业者在接受或拒绝现有科学范式方面有多大自由度存在模糊性。通过分析选择用抗抑郁药治疗抑郁儿童的儿童精神科医生和儿科医生当前面临的问题,探讨了这一困境的本质。尽管双盲研究的文献一致表明,抗抑郁药在治疗儿童和青少年抑郁症方面并不比安慰剂更有效,但这类药物仍在广泛使用。文中考虑了用于解决这类矛盾的策略,并对某些伦理难题进行了评估。